In heterogeneous catalysis, the catalyst is in a different phase from the reactants. Product Details of 4442-53-9, However, they have proven to be challenging because of the mutual inactivation of both catalysts. 4442-53-9, name is 2,3-Dihydrobenzo[b][1,4]dioxine-5-carboxylic acid. In an article，Which mentioned a new discovery about 4442-53-9
A Developability-Focused Optimization Approach Allows Identification of in Vivo Fast-Acting Antimalarials: N -[3-[(Benzimidazol-2-yl)amino]propyl]amides
Malaria continues to be a major global health problem, being particularly devastating in the African population under the age of five. Artemisinin-based combination therapies (ACTs) are the first-line treatment recommended by the WHO to treat Plasmodium falciparum malaria, but clinical resistance against them has already been reported. As a consequence, novel chemotypes are urgently needed. Herein we report a novel, in vivo active, fast-acting antimalarial chemotype based on a benzimidazole core. This discovery is the result of a medicinal chemistry plan focused on improving the developability profile of an antichlamydial chemical class previously reported by our group. (Graph Presented).
If you are interested in 4442-53-9, you can contact me at any time and look forward to more communication. Product Details of 4442-53-9